stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) Revenue
Revolution Medicines, Inc.'s revenue for fiscal 2023 was $11.6M, down 67.3% from $35.4M in fiscal 2022. Over the twelve months to 30 September 2026 it was $209.1M. Over the past ten years it has ranged from $11.6M (fiscal 2023) to $50.0M (fiscal 2019) — the current reading is the lowest in ten years. Revolution Medicines, Inc. ranks 70th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2023 | $11.6M | (67.27%) |
| FY2022 | $35.4M | 20.38% |
| FY2021 | $29.4M | (31.62%) |
| FY2020 | $43.0M | (14.10%) |
| FY2019 | $50.0M | 148.16% |
| FY2018 | $20.2M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $197.6M | 26,525.20% |
| Dec 2023 | $742.0K | (80.60%) |
| Jun 2023 | $3.8M | (45.48%) |
| Mar 2023 | $7.0M | (54.25%) |
| 16 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $6.6B |
| INCY Incyte Corporation compare | $6.0B |
| ARGX argenex SE compare | $5.9B |
| GMAB Genmab A/S Sponsored ADR compare | $4.1B |
| BNTX BioNTech SE Sponsored ADR compare | $2.7B |
| RPRX Royalty Pharma PLC compare | $2.6B |
| INSM Insmed, Inc. compare | $1.5B |
| RVMD Revolution Medicines, Inc. | $209.1M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RVMD
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement